Eyenovia has seen its stock price plummet by more than two-thirds after a Phase III study of its drug-device combination for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback